[HTML][HTML] Why 90% of clinical drug development fails and how to improve it?
Ninety percent of clinical drug development fails despite implementation of many successful
strategies, which raised the question whether certain aspects in target validation and drug …
strategies, which raised the question whether certain aspects in target validation and drug …
Remdesivir against COVID-19 and other viral diseases
JJ Malin, I Suárez, V Priesner… - Clinical microbiology …, 2020 - Am Soc Microbiol
Patients and physicians worldwide are facing tremendous health care hazards that are
caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS …
caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
[HTML][HTML] Remdesivir for the treatment of COVID‐19
F Grundeis, K Ansems, K Dahms… - … of systematic reviews, 2023 - ncbi.nlm.nih.gov
Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
HXJ Lin, S Cho, V Meyyur Aravamudan, HY Sanda… - Infection, 2021 - Springer
COVID-19 is an infectious disease caused by a novel β-coronavirus, belonging to the same
subgenus as the Severe Acute Respiratory Syndrome (SARS) virus. Remdesivir, an …
subgenus as the Severe Acute Respiratory Syndrome (SARS) virus. Remdesivir, an …
[HTML][HTML] Development of remdesivir as a dry powder for inhalation by thin film freezing
S Sahakijpijarn, C Moon, JJ Koleng, DJ Christensen… - Pharmaceutics, 2020 - mdpi.com
Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for
emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry …
emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry …
Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission
The highly infective coronavirus disease 19 (COVID-19) is caused by a novel strain of
coronaviruses–the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
coronaviruses–the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro
Aim: To formulate an aerosolized nanoliposomal carrier for remdesivir (AL-Rem) against
coronavirus disease 2019. Methods: AL-Rem was prepared using modified hydration …
coronavirus disease 2019. Methods: AL-Rem was prepared using modified hydration …
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify …
Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition
Recently, a novel coronavirus, known as severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has raised global concerns, being the etiological agent of the current …
(SARS-CoV-2), has raised global concerns, being the etiological agent of the current …